Skip to content
Aminoscope
Head-to-head

GHK-Cu vs TB-500

Both are sold as repair peptides, but each one's only real human data sits somewhere narrow and unrelated: a cosmetic cream for one, a dry-eye drop for the other.

By Julian RothResearch & dataUpdated October 2026

Short answer

GHK-Cu and TB-500 are both graded preclinical / minimal, which leaves little or no controlled human data to choose between them. What does differ is access, since GHK-Cu is sold in cosmetic skin-care products, while TB-500 is sold gray-market as a research chemical. GHK-Cu is the one sold for skin and hair, while TB-500 targets recovery and tissue repair.

GHK-Cu

Copper tripeptide

Preclinical / minimal

Real tissue-remodeling biology, mostly in-vitro and topical; a cosmetic signal, not systemic anti-aging proof.

Full GHK-Cu evidence review

TB-500

Thymosin β4

Preclinical / minimal

Mechanistic and early-stage human work (e.g. ophthalmology); no performance or recovery outcome trials.

Full TB-500 evidence review

GHK-Cu vs TB-500: head to head

FDA status / approved use

GHK-Cu

Long-established cosmetic ingredient in skincare creams and serums

TB-500

Not an approved drug; prohibited in sport by WADA
Marketed for

GHK-Cu

Skin, hair, 'anti-aging'

TB-500

Recovery, tissue repair
Outcome areas

GHK-Cu

Skin / hair; Longevity / lifespan

TB-500

Injury recovery / tissue repair
Evidence grade

GHK-Cu

Preclinical / minimal

TB-500

Preclinical / minimal
How it works

GHK-Cu

Copper-binding tripeptide that stimulates collagen synthesis in lab studies

TB-500

Binds and sequesters G-actin, regulating the cytoskeleton and cell migration
Route and dosing

GHK-Cu

Topical cream or serum; injected forms are also sold

TB-500

Injectable; no established dose
Headline human result

GHK-Cu

Not established

TB-500

Not established
Strongest evidence

GHK-Cu

J Biomater Sci, 2008. Little or no controlled human outcome data for the marketed useGHK-Cu evidence reviewPubMed 18644225

TB-500

Expert Opin Biol Ther, 2018. Little or no controlled human outcome data for the marketed useTB-500 evidence reviewPubMed 30063853
Key safety signal

GHK-Cu

Injected form has no established dosing or long-term safety data; copper can be toxic in excess

TB-500

No human efficacy trials, established dose or long-term safety data for the injectable
How it is obtained

GHK-Cu

Sold in cosmetic skin-care products

TB-500

Sold gray-market as a research chemical; no approved or legitimately compounded human product

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

Preclinical / minimal:
Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.

Our verdict

Neither supports the systemic tissue-repair use it is marketed for. GHK-Cu's human evidence is limited to small cosmetic studies of topical copper-peptide creams; its regenerative and gene-expression findings are in vitro and animal work, and the injected form has no human efficacy trials or established dosing. Thymosin beta-4 does have randomized human data, but it comes from Phase 2 trials of an ophthalmic solution for severe dry eye, not from the injectable TB-500 sold for muscle and tendon recovery, which has no published human efficacy trials, no established dose, and is prohibited in sport by the World Anti-Doping Agency. They have not been compared directly, and neither is an approved drug.

GHK-Cu fits if

Someone whose actual goal is skin, where the topical route is the lowest-risk lane and the modest cosmetic evidence at least matches the use.

TB-500 fits if

Someone interested in actin-sequestering repair biology or the ophthalmology program specifically, and who does not mistake that eye-drop trial for the vial sold for recovery.

GHK-Cu vs TB-500: common questions

Is either GHK-Cu or TB-500 FDA-approved?
No. GHK-Cu is a long-established cosmetic ingredient in skincare creams and serums. TB-500 is not an approved drug; prohibited in sport by WADA.
Which has stronger human evidence, GHK-Cu or TB-500?
Neither. Both are graded preclinical / minimal, with little or no controlled human outcome data for the marketed use. The key source for GHK-Cu is J Biomater Sci, 2008; for TB-500, it is Expert Opin Biol Ther, 2018.
What are the main safety concerns with GHK-Cu and TB-500?
With GHK-Cu, injected form has no established dosing or long-term safety data; copper can be toxic in excess. TB-500 has no human efficacy trials, established dose or long-term safety data for the injectable.

Key studies behind each

GHK-Cu

  1. Pickart L. (2008). The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. PubMed 18644225
  2. Pickart L, Vasquez-Soltero JM, Margolina A. (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. PubMed 26236730
  3. Pickart L, Margolina A. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. PubMed 29986520
  4. Dou Y, Lee A, Zhu L, et al. (2020). The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther. PubMed 35083444

TB-500

  1. Sosne G. (2018). Thymosin beta 4 and the eye: the journey from bench to bedside. Expert Opin Biol Ther. PubMed 30063853
  2. Sosne G, Dunn SP, Kim C. (2015). Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. PubMed 25826322
  3. Sosne G, Ousler GW. (2015). Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clin Ophthalmol. PubMed 26056426
  4. Xiong Y, Mahmood A, Meng Y, et al. (2012). Neuroprotective and neurorestorative effects of thymosin β4 treatment following experimental traumatic brain injury. Ann N Y Acad Sci. PubMed 23050817

The full evidence reviews

Where to get it

Where to get peptide therapy

Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm GHK-Cu availability before ordering.

Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.

Compare all 204 peptide-therapy providers →

Provider reviews we publish: Live VitalCalifornia Trim ClinicDr. Gillis' Wellness CenterElitePhysiqMDEmbraceRXEvolve Telemed

Related comparisons